Next-Generation Sequencing:Article Title: External Validation of a CT-Based Radiogenomics Model for the Detection of EGFR Mutation in NSCLC and the Impact of Prevalence in Model Building by Using Synthetic Minority Over Sampling (SMOTE): Lessons Learned.
Article Snippet: .. Meanwhile, in our cohort molecular profiling was performed using five different next-generation sequencing (NGS) panels: a custom multiplex genotyping panel on a matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) massspectrometry platform (MassAR-RAY, Agena Bioscience, San Diego, CA) to genotype 279 mutations within 23 genes; the TruSeq Amplicon Cancer Panel (TSACP, Illumina) on the MiSeq sequencer (Illumina) covering regions of 48 genes; the Ion AmpliSeq Cancer Panel (ASCP, ThermoFisher Scientific) on the Ion Proton sequencer (ThermoFisher Scientific) covering regions of 50 genes, a custom hybridization capture panel [SureSelect (Agilent, Santa Clara, CA)] of 555 cancer-relevant genes sequenced on a NextSeq series sequencing system (Illumina, San Diego, CA) and a commercial 161-gene amplicon DNA/RNA panel (Oncomine Comprehensive Assay v3: ThermoFisher Scientific, Waltham, MA) sequenced on the Ion S5 XL platform (ThermoFisher Scientific). .. Multiple genes, that have been previously reported as altered in NSCLC, were collected from a web-based resource (cBioPortal.ca for Cancer Genomics (38,39)) and were categorized in significantly mutated genes, oncogenes and tumor suppressor genes.
Article Title: Contrast Enhanced CT Radiogenomics in a Retrospective NSCLC Cohort: Models, Attempted Validation of a Published Model and the Relevance of the Clinical Context.
Article Snippet: .. Molecular profiling was performed using five different next-generation sequencing (NGS) panels: a custom multiplex genotyping panel on a matrix-assisted laser desorption/ ionization time-of-flight (MALDI-TOF) mass-spectrometry platform (MassAR- RAY, Agena Bioscience, San Diego, CA, USA) to genotype 279 mutations within 23 genes; the TruSeq Amplicon Cancer Panel (TSACP, Illumina) on the MiSeq sequencer (Illumina) covering regions of 48 genes; the Ion AmpliSeq Cancer Panel (ASCP, ThermoFisher Scientific) on the Ion Proton sequencer (ThermoFisher Scientific) covering regions of 50 genes, a custom hybridization capture panel [SureSelect (Agilent, Santa Clara, CA, U.S.A.)] of 555 cancer-relevant genes sequenced on a NextSeq series sequencing system (Illumina, San Diego, CA, U.S.A.) and a commercial 161- gene amplicon DNA/RNA panel (Oncomine Comprehensive Assay v3: ThermoFisher Scientific, Waltham, MA, U.S.A.) sequenced on the Ion S5 XL platform (ThermoFisher Scientific). .. Multiple genes, that have been previously reported as altered in NSCLC, were collected from a web-based resource (cBioPortal.ca for Cancer Genomics (36,37)) and were categorized in significantly mutated genes, oncogenes and tumor suppressor genes.
Multiplex Assay:Article Title: External Validation of a CT-Based Radiogenomics Model for the Detection of EGFR Mutation in NSCLC and the Impact of Prevalence in Model Building by Using Synthetic Minority Over Sampling (SMOTE): Lessons Learned.
Article Snippet: .. Meanwhile, in our cohort molecular profiling was performed using five different next-generation sequencing (NGS) panels: a custom multiplex genotyping panel on a matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) massspectrometry platform (MassAR-RAY, Agena Bioscience, San Diego, CA) to genotype 279 mutations within 23 genes; the TruSeq Amplicon Cancer Panel (TSACP, Illumina) on the MiSeq sequencer (Illumina) covering regions of 48 genes; the Ion AmpliSeq Cancer Panel (ASCP, ThermoFisher Scientific) on the Ion Proton sequencer (ThermoFisher Scientific) covering regions of 50 genes, a custom hybridization capture panel [SureSelect (Agilent, Santa Clara, CA)] of 555 cancer-relevant genes sequenced on a NextSeq series sequencing system (Illumina, San Diego, CA) and a commercial 161-gene amplicon DNA/RNA panel (Oncomine Comprehensive Assay v3: ThermoFisher Scientific, Waltham, MA) sequenced on the Ion S5 XL platform (ThermoFisher Scientific). .. Multiple genes, that have been previously reported as altered in NSCLC, were collected from a web-based resource (cBioPortal.ca for Cancer Genomics (38,39)) and were categorized in significantly mutated genes, oncogenes and tumor suppressor genes.
Article Title: Contrast Enhanced CT Radiogenomics in a Retrospective NSCLC Cohort: Models, Attempted Validation of a Published Model and the Relevance of the Clinical Context.
Article Snippet: .. Molecular profiling was performed using five different next-generation sequencing (NGS) panels: a custom multiplex genotyping panel on a matrix-assisted laser desorption/ ionization time-of-flight (MALDI-TOF) mass-spectrometry platform (MassAR- RAY, Agena Bioscience, San Diego, CA, USA) to genotype 279 mutations within 23 genes; the TruSeq Amplicon Cancer Panel (TSACP, Illumina) on the MiSeq sequencer (Illumina) covering regions of 48 genes; the Ion AmpliSeq Cancer Panel (ASCP, ThermoFisher Scientific) on the Ion Proton sequencer (ThermoFisher Scientific) covering regions of 50 genes, a custom hybridization capture panel [SureSelect (Agilent, Santa Clara, CA, U.S.A.)] of 555 cancer-relevant genes sequenced on a NextSeq series sequencing system (Illumina, San Diego, CA, U.S.A.) and a commercial 161- gene amplicon DNA/RNA panel (Oncomine Comprehensive Assay v3: ThermoFisher Scientific, Waltham, MA, U.S.A.) sequenced on the Ion S5 XL platform (ThermoFisher Scientific). .. Multiple genes, that have been previously reported as altered in NSCLC, were collected from a web-based resource (cBioPortal.ca for Cancer Genomics (36,37)) and were categorized in significantly mutated genes, oncogenes and tumor suppressor genes.
Amplification:Article Title: External Validation of a CT-Based Radiogenomics Model for the Detection of EGFR Mutation in NSCLC and the Impact of Prevalence in Model Building by Using Synthetic Minority Over Sampling (SMOTE): Lessons Learned.
Article Snippet: .. Meanwhile, in our cohort molecular profiling was performed using five different next-generation sequencing (NGS) panels: a custom multiplex genotyping panel on a matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) massspectrometry platform (MassAR-RAY, Agena Bioscience, San Diego, CA) to genotype 279 mutations within 23 genes; the TruSeq Amplicon Cancer Panel (TSACP, Illumina) on the MiSeq sequencer (Illumina) covering regions of 48 genes; the Ion AmpliSeq Cancer Panel (ASCP, ThermoFisher Scientific) on the Ion Proton sequencer (ThermoFisher Scientific) covering regions of 50 genes, a custom hybridization capture panel [SureSelect (Agilent, Santa Clara, CA)] of 555 cancer-relevant genes sequenced on a NextSeq series sequencing system (Illumina, San Diego, CA) and a commercial 161-gene amplicon DNA/RNA panel (Oncomine Comprehensive Assay v3: ThermoFisher Scientific, Waltham, MA) sequenced on the Ion S5 XL platform (ThermoFisher Scientific). .. Multiple genes, that have been previously reported as altered in NSCLC, were collected from a web-based resource (cBioPortal.ca for Cancer Genomics (38,39)) and were categorized in significantly mutated genes, oncogenes and tumor suppressor genes.
Article Title: Contrast Enhanced CT Radiogenomics in a Retrospective NSCLC Cohort: Models, Attempted Validation of a Published Model and the Relevance of the Clinical Context.
Article Snippet: .. Molecular profiling was performed using five different next-generation sequencing (NGS) panels: a custom multiplex genotyping panel on a matrix-assisted laser desorption/ ionization time-of-flight (MALDI-TOF) mass-spectrometry platform (MassAR- RAY, Agena Bioscience, San Diego, CA, USA) to genotype 279 mutations within 23 genes; the TruSeq Amplicon Cancer Panel (TSACP, Illumina) on the MiSeq sequencer (Illumina) covering regions of 48 genes; the Ion AmpliSeq Cancer Panel (ASCP, ThermoFisher Scientific) on the Ion Proton sequencer (ThermoFisher Scientific) covering regions of 50 genes, a custom hybridization capture panel [SureSelect (Agilent, Santa Clara, CA, U.S.A.)] of 555 cancer-relevant genes sequenced on a NextSeq series sequencing system (Illumina, San Diego, CA, U.S.A.) and a commercial 161- gene amplicon DNA/RNA panel (Oncomine Comprehensive Assay v3: ThermoFisher Scientific, Waltham, MA, U.S.A.) sequenced on the Ion S5 XL platform (ThermoFisher Scientific). .. Multiple genes, that have been previously reported as altered in NSCLC, were collected from a web-based resource (cBioPortal.ca for Cancer Genomics (36,37)) and were categorized in significantly mutated genes, oncogenes and tumor suppressor genes.
Hybridization:Article Title: External Validation of a CT-Based Radiogenomics Model for the Detection of EGFR Mutation in NSCLC and the Impact of Prevalence in Model Building by Using Synthetic Minority Over Sampling (SMOTE): Lessons Learned.
Article Snippet: .. Meanwhile, in our cohort molecular profiling was performed using five different next-generation sequencing (NGS) panels: a custom multiplex genotyping panel on a matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) massspectrometry platform (MassAR-RAY, Agena Bioscience, San Diego, CA) to genotype 279 mutations within 23 genes; the TruSeq Amplicon Cancer Panel (TSACP, Illumina) on the MiSeq sequencer (Illumina) covering regions of 48 genes; the Ion AmpliSeq Cancer Panel (ASCP, ThermoFisher Scientific) on the Ion Proton sequencer (ThermoFisher Scientific) covering regions of 50 genes, a custom hybridization capture panel [SureSelect (Agilent, Santa Clara, CA)] of 555 cancer-relevant genes sequenced on a NextSeq series sequencing system (Illumina, San Diego, CA) and a commercial 161-gene amplicon DNA/RNA panel (Oncomine Comprehensive Assay v3: ThermoFisher Scientific, Waltham, MA) sequenced on the Ion S5 XL platform (ThermoFisher Scientific). .. Multiple genes, that have been previously reported as altered in NSCLC, were collected from a web-based resource (cBioPortal.ca for Cancer Genomics (38,39)) and were categorized in significantly mutated genes, oncogenes and tumor suppressor genes.
Article Title: Contrast Enhanced CT Radiogenomics in a Retrospective NSCLC Cohort: Models, Attempted Validation of a Published Model and the Relevance of the Clinical Context.
Article Snippet: .. Molecular profiling was performed using five different next-generation sequencing (NGS) panels: a custom multiplex genotyping panel on a matrix-assisted laser desorption/ ionization time-of-flight (MALDI-TOF) mass-spectrometry platform (MassAR- RAY, Agena Bioscience, San Diego, CA, USA) to genotype 279 mutations within 23 genes; the TruSeq Amplicon Cancer Panel (TSACP, Illumina) on the MiSeq sequencer (Illumina) covering regions of 48 genes; the Ion AmpliSeq Cancer Panel (ASCP, ThermoFisher Scientific) on the Ion Proton sequencer (ThermoFisher Scientific) covering regions of 50 genes, a custom hybridization capture panel [SureSelect (Agilent, Santa Clara, CA, U.S.A.)] of 555 cancer-relevant genes sequenced on a NextSeq series sequencing system (Illumina, San Diego, CA, U.S.A.) and a commercial 161- gene amplicon DNA/RNA panel (Oncomine Comprehensive Assay v3: ThermoFisher Scientific, Waltham, MA, U.S.A.) sequenced on the Ion S5 XL platform (ThermoFisher Scientific). .. Multiple genes, that have been previously reported as altered in NSCLC, were collected from a web-based resource (cBioPortal.ca for Cancer Genomics (36,37)) and were categorized in significantly mutated genes, oncogenes and tumor suppressor genes.
Sequencing:Article Title: External Validation of a CT-Based Radiogenomics Model for the Detection of EGFR Mutation in NSCLC and the Impact of Prevalence in Model Building by Using Synthetic Minority Over Sampling (SMOTE): Lessons Learned.
Article Snippet: .. Meanwhile, in our cohort molecular profiling was performed using five different next-generation sequencing (NGS) panels: a custom multiplex genotyping panel on a matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) massspectrometry platform (MassAR-RAY, Agena Bioscience, San Diego, CA) to genotype 279 mutations within 23 genes; the TruSeq Amplicon Cancer Panel (TSACP, Illumina) on the MiSeq sequencer (Illumina) covering regions of 48 genes; the Ion AmpliSeq Cancer Panel (ASCP, ThermoFisher Scientific) on the Ion Proton sequencer (ThermoFisher Scientific) covering regions of 50 genes, a custom hybridization capture panel [SureSelect (Agilent, Santa Clara, CA)] of 555 cancer-relevant genes sequenced on a NextSeq series sequencing system (Illumina, San Diego, CA) and a commercial 161-gene amplicon DNA/RNA panel (Oncomine Comprehensive Assay v3: ThermoFisher Scientific, Waltham, MA) sequenced on the Ion S5 XL platform (ThermoFisher Scientific). .. Multiple genes, that have been previously reported as altered in NSCLC, were collected from a web-based resource (cBioPortal.ca for Cancer Genomics (38,39)) and were categorized in significantly mutated genes, oncogenes and tumor suppressor genes.
Article Title: Contrast Enhanced CT Radiogenomics in a Retrospective NSCLC Cohort: Models, Attempted Validation of a Published Model and the Relevance of the Clinical Context.
Article Snippet: .. Molecular profiling was performed using five different next-generation sequencing (NGS) panels: a custom multiplex genotyping panel on a matrix-assisted laser desorption/ ionization time-of-flight (MALDI-TOF) mass-spectrometry platform (MassAR- RAY, Agena Bioscience, San Diego, CA, USA) to genotype 279 mutations within 23 genes; the TruSeq Amplicon Cancer Panel (TSACP, Illumina) on the MiSeq sequencer (Illumina) covering regions of 48 genes; the Ion AmpliSeq Cancer Panel (ASCP, ThermoFisher Scientific) on the Ion Proton sequencer (ThermoFisher Scientific) covering regions of 50 genes, a custom hybridization capture panel [SureSelect (Agilent, Santa Clara, CA, U.S.A.)] of 555 cancer-relevant genes sequenced on a NextSeq series sequencing system (Illumina, San Diego, CA, U.S.A.) and a commercial 161- gene amplicon DNA/RNA panel (Oncomine Comprehensive Assay v3: ThermoFisher Scientific, Waltham, MA, U.S.A.) sequenced on the Ion S5 XL platform (ThermoFisher Scientific). .. Multiple genes, that have been previously reported as altered in NSCLC, were collected from a web-based resource (cBioPortal.ca for Cancer Genomics (36,37)) and were categorized in significantly mutated genes, oncogenes and tumor suppressor genes.
|
agena bioscience is a verified supplier 
agena bioscience manufactures this product 